A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 19, 2023

Primary Completion Date

August 30, 2025

Study Completion Date

August 30, 2027

Conditions
Relapsed Advanced Lymphomas
Interventions
DRUG

AUR108

3 Days dosing, and 4 days no dose in a week

Trial Locations (20)

10029

RECRUITING

All India Institute of Medical Sciences, Delhi

110085

RECRUITING

Rajiv Gandhi Cancer Institute and Research Centre, Delhi

160012

RECRUITING

Post Graduate Institute of Medical Education & Research,, Chandigarh

190010

RECRUITING

Super Specialty Hospital (G.M.C) Srinagar, Srinagar

380015

RECRUITING

HCC Happiness Care and Cure Multispeciality Hospital, Ahmedabad

395002

RECRUITING

Unique Hospital, Surat

395004

RECRUITING

Kiran Multi Speciality Hospital, Surat

400056

RECRUITING

Mumbai Onco Care Centre, Mumbai

411004

RECRUITING

Deenanath Mangeshkar Hospital & Research Center, Pune

RECRUITING

MTES Sanjeevan Hospital, Pune

416234

RECRUITING

Kolhapur Cancer Centre, Kolhāpur

422002

RECRUITING

HCG Manavata Cancer Centre, Nashik

441108

RECRUITING

All India Institute of Medical Sciences, Nagpur

444606

RECRUITING

Sujan Surgical Cancer Hospital and Amravati Cancer Foundation, Amravati

500004

RECRUITING

MNJ Institute of Oncology and Regional Cancer Centre, Hyderabad

530040

RECRUITING

Omega Cancer Hospitals, Visakhapatnam

590010

RECRUITING

KLES Dr Prabhakar Kore Hospital and MRC, Belagavi

682041

RECRUITING

Amrita Institute of Medical Sciences (AIMS), Kochi

700160

RECRUITING

Tata Medical Center, Kolkata

751007

RECRUITING

Sparsh Hospital and Critical Care (P) Ltd., Bhubaneswar

All Listed Sponsors
lead

Aurigene Discovery Technologies Limited

INDUSTRY